Press

Universal Ibogaine Featured in Psychedelics Tonight Documentary Series

Sep 26 • 2 min read

Universal Ibogaine Inc.(TSXV:IBO), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, is pleased to announce it has been featured in a documentary series entitled Psychedelics Tonight, which was co-produced by Kyle Buller and Joe Moore of Psychedelics Today in partnership with ALTRD.TV. The docuseries provides information on the history and future potential of several…

Clearmind Announces Notice of Proposed Stock Consolidation

Sep 25 • 2 min read

Clearmind Medicine Inc. (CSE: CMND | OTC Pink: CMNDF | FSE: CWY0), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, announces that it will be consolidating all of the issued and outstanding common shares of the Company on the basis of one (1) post consolidation…

Irwin Naturals Inc Announces Normal Course Issuer Bid for Subordinate Voting Shares of the Corporation

Sep 24 • 3 min read

Irwin Naturals Inc. (CSE: IWIN | OTC: IWINF | FRA: 97X) announced today its intention to commence a normal course issuer bid, under which the Company may purchase up to 75,466 of the Company’s Subordinate Voting Shares over a 12-month period, representing approximately 5% of its issued and outstanding SVS as of September 26, 2022. The Company is…

Optimi Health, ATMA Journey Centers To Proceed With Phase I Natural Psilocybin and MDMA Clinical Trial Application to Health Canada

Sep 24 • 5 min read

Optimi Health Corp. (CSE: OPTI | OTCQX: OPTHF | FRA: 8BN), a Canadian-based company licensed by Health Canada to produce and supply natural, EU-GMP grade psilocybin and other psychedelic substances, most notably MDMA, is pleased to announce that in conjunction with ATMA Journey Centers, the companies have confirmed their intent to proceed with a Phase…

Core One Labs Signs Letter of Intent with GMP Manufacturing Partner for Production of Proprietary Psychedelic Compounds

Sep 24 • 4 min read

Core One Labs Inc. (CSE:COOL), (OTCQB:CLABF), (Frankfurt:LD6, WKN:A3CSSU) is pleased to announce it has entered into a Letter of Intent with Medelys Laboratories International Inc. dated effective September 21, 2022, for the purpose of manufacturing the Company’s proprietary psychedelic active pharmaceutical ingredient (API) products for Core One and its subsidiaries. Under the Manufacturing Arrangement, it is…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435